Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

This trial tests whether a precision treatment approach guided by AI deep-learning models — analyzing a patient's tumor tissue, imaging, and genetic data — can better match people with unresectable liver cancer (HCC) to a combination treatment of HAIC chemotherapy, lenvatinib (a targeted drug), and a PD-1 immunotherapy. **You may be eligible if...** - You are between 18 and 75 years old - You have hepatocellular carcinoma confirmed by biopsy that cannot be surgically removed - You have not previously received any treatment for your liver cancer - Your liver function is reasonably preserved (Child-Pugh ≤7, ECOG 0–1) - The AI model suggests you are likely to benefit from HAIC plus combination treatment **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have had gastrointestinal bleeding in the past 4 weeks or have high bleeding risk - You have an active infection - You have serious organ conditions affecting drug absorption or clearance Talk to your doctor to see if this trial is right for you.